Daiichi Sankyo

Basic Information

Stock Code
4568
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
September 2005
Listing Year
September 2005
Official Website
https://www.daiichisankyo.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kyowa Kirin, Takeda, Astellas, Shionogi, Chugai, Eisai, Ono Pharmaceutical, Kissei Pharmaceutical, Santen Pharmaceutical, Otsuka Holdings

Overview

Daiichi Sankyo is a major Japanese pharmaceutical company established in 2005, specializing in prescription drugs with strengths in its unique R&D capabilities and global expansion, giving it competitiveness in international markets.

Current Situation

Daiichi Sankyo recorded consolidated net sales of 1.6016 trillion yen, operating income of 195.2 billion yen, and net income of 201 billion yen for the fiscal year ending March 2024, boasting the fourth-largest sales in the domestic pharmaceutical industry. The company focuses on prescription pharmaceuticals, particularly oncology, with aggressive investments in drug discovery and R&D to expand in global markets. It has bases in Asia, North America, and Europe, and conducts manufacturing and sales of pharmaceuticals through subsidiaries. As of January 2023, it leads the pharmaceutical sector in market capitalization and is a constituent of major indices such as TOPIX Core 30 and Nikkei 225. Passionate about innovation, it focuses on developing anticancer agents and biologics while promoting collaborations with major pharmaceutical companies. Emphasizing corporate social responsibility, it actively engages in sustainable drug development, environmental protection, and regional contributions. In the medium to long term, it aims to accelerate new targeted drugs and biologics development, strengthen digital health initiatives, and elevate its position as a global pharmaceutical company by 2030.

Trivia

Interesting Facts

  • Born from the 2005 management integration of Sankyo and Daiichi Pharmaceutical.
  • Holds significant influence domestically and internationally in anticancer agents.
  • Characteristic focus solely on prescription pharmaceuticals.
  • Strength in Asian markets as a global pharmaceutical company.
  • Drug discovery platform and AI technology for new drug development support.
  • Jointly developed world-class anticancer agent 'Enhertu' with Korean company.
  • Built advanced vaccine manufacturing system centered on Daiichi Sankyo Biotech.
  • One of Japan's representative pharmaceutical companies as a Nikkei 225 constituent.
  • Deploys customer-close services with sales organization specialized for hospitals.
  • Promotes industry-academia collaboration for innovative pharmaceuticals via medical research ties.
  • Stable high-quality pharmaceutical supply via group of manufacturing subsidiaries.
  • Social recognition through business operations considerate of sustainability.
  • Actively promotes disabled employment via special subsidiary.
  • Inherits history of former Daiichi Pharmaceutical and Sankyo with long industry experience.
  • Business diversification via pharmaceutical logistics and clinical development support subsidiaries.

Hidden Connections

  • Acquired Zepharma from Astellas Pharma, inheriting quasi-drug business for market expansion.
  • Integrated manufacturing subsidiaries from former Sankyo and Daiichi groups for efficient production.
  • Strengthened collaboration with Korean company Biomarker on joint anticancer agent development.
  • Established position competing with and collaborating with world's top pharmaceutical companies.
  • Attracts attention from financial institutions across sectors as representative TOPIX stock.
  • Promotes social responsibility by establishing special subsidiary compliant with disabled employment promotion law.
  • Aggressively expands multinationally via local corporations and subsidiaries in Asia and the West.
  • Deep ties with local communities through medical-related CSR and health education support.

Future Outlook

Growth Drivers

  • Expansion of global pharmaceutical market, especially rising demand in Asia
  • New drug creation and expansion centered on anticancer agents
  • R&D efficiency gains from AI technology and drug discovery platform innovation
  • Growth in biopharmaceuticals and vaccine markets
  • Revenue base strengthening via diversification of healthcare services
  • Corporate value enhancement through sustainable development and environmental considerations
  • Advances in digital health and telemedicine fields
  • Efficiency gains from regulatory easing and international approval processes
  • Heightened M&A and partnership activity in pharmaceutical industry
  • Rising medical needs from aging population
  • Differentiation strategies amid domestic generic shift
  • Increased vaccine demand from heightened public health awareness

Strategic Goals

  • Achieve over 60% global sales ratio
  • Strengthen pipeline via accelerated innovative new drug development
  • Realize sustainable environmental goals and net zero
  • Become a major player in digital health
  • Expand CSR activities rooted in communities for social contribution
  • Foster organizational culture promoting diversity and inclusion
  • Efficiency and safety enhancement in manufacturing and logistics
  • Strengthen international regulatory compliance and rapid product approvals
  • Expand presence in emerging markets
  • Strengthen management structure and advanced governance

Business Segments

Pharmaceutical Manufacturing Contract

Overview
Provides contract manufacturing services for investigational drugs and pharmaceuticals, achieving advanced quality control.
Competitiveness
Advanced GMP compliance and quality assurance system
Customers
  • Domestic and international pharmaceutical companies
  • Biotechnology companies
  • Investigational drug developers
  • Research institutions
Products
  • Investigational drug manufacturing
  • Biopharmaceutical manufacturing
  • API manufacturing
  • Intermediate manufacturing

R&D Support Services

Overview
Advanced technical services supporting drug discovery and clinical development.
Competitiveness
Specialized research expertise and networks
Customers
  • Pharmaceutical research institutions
  • University labs
  • Medical institutions
Products
  • Drug discovery support
  • Clinical trial support
  • Biomarker development

Pharmaceutical Raw Materials Supply

Overview
Stable supply of raw materials foundational to pharmaceutical manufacturing.
Competitiveness
Long years of manufacturing technology and supply reliability
Customers
  • Pharmaceutical companies
  • API manufacturers
Products
  • Organic synthesis raw materials
  • Biologically derived raw materials
  • Intermediates

Biopharmaceutical Development

Overview
Provides pharmaceutical development services using cutting-edge biotech.
Competitiveness
Abundant development track record and technical capabilities
Customers
  • Pharmaceutical companies
  • Biotech ventures
Products
  • Antibody pharmaceuticals
  • Gene therapy products

Vaccine Manufacturing Contract

Overview
Performs high-quality vaccine manufacturing and contract development.
Competitiveness
High-safety manufacturing technology and track record
Customers
  • Government agencies
  • Pharmaceutical manufacturers
  • Research institutions
Products
  • Influenza vaccines
  • Novel vaccine manufacturing

Pharmaceutical Logistics Services

Overview
Provides quality maintenance and efficient delivery for pharmaceuticals.
Competitiveness
Wide-area coverage via domestic and international bases
Customers
  • Pharmaceutical companies
  • Medical institutions
  • Wholesalers
Products
  • Temperature-controlled logistics
  • Inventory management
  • Delivery services

Clinical Trial Contracts

Overview
Provides high-quality contract support for clinical trials.
Competitiveness
Abundant domestic and international trial experience
Customers
  • Pharmaceutical companies
  • Biotech ventures
  • Research institutions
Products
  • Trial design
  • Patient recruitment
  • Data management

Drug Discovery Platform Development

Overview
Provides drug discovery platforms utilizing AI technology.
Competitiveness
Industry-leading AI utilization capabilities
Customers
  • Pharmaceutical companies
  • Research institutions
Products
  • High-throughput screening
  • AI drug discovery support

Medical Device Manufacturing

Overview
Develops and manufactures medical devices.
Competitiveness
Product development leveraging pharmaceutical know-how
Customers
  • Medical device manufacturers
  • Hospitals
Products
  • Syringes
  • Diagnostic kits

Environmental Analysis and Safety Evaluation

Overview
Evaluates drug safety and environmental impact.
Competitiveness
Long-term track record in reliability evaluation
Customers
  • Pharmaceutical companies
  • Regulatory authorities
  • Research institutions
Products
  • Toxicity testing
  • Environmental impact assessment

Digital Health Collaboration Services

Overview
Deploys services fusing digital technology and healthcare.
Competitiveness
Health management linked to pharmaceutical development
Customers
  • Medical institutions
  • Insurers
  • IT companies
Products
  • Health management apps
  • Telemedicine support

Licensing and Partnerships

Overview
Conducts technology and product licensing, joint development.
Competitiveness
Partnership strength leveraging global networks
Customers
  • Domestic and international pharmaceutical companies
  • Biotech companies
Products
  • New drug patents
  • Joint R&D

Competitive Advantage

Strengths

  • High market share in domestic pharmaceutical market
  • Innovative anticancer drug development capabilities
  • Global manufacturing and sales bases
  • Robust R&D organization
  • Diverse prescription product portfolio
  • Stable financial base
  • Extensive sales network
  • Technology acquisition through multilateral partnerships
  • Robust quality management system
  • Technological superiority via patents
  • Influence in Asian markets
  • Separation of healthcare and pharmaceutical operations
  • Brand recognition within the industry
  • Strong relationships with healthcare professionals
  • Regulatory compliance capabilities in multiple countries

Competitive Advantages

  • Outstanding development capabilities for innovative drugs starting with anticancer agents
  • Global deployment with manufacturing and sales networks in multiple regions
  • Advanced technology in biopharmaceuticals
  • Aggressive R&D investment strengthening new drug creation
  • Sustainable development and environmental considerations at strategy core
  • Competitive edge secured through strong IP management and patent activities
  • Technology base strengthened by diverse partnerships with major domestic and international companies
  • Enhanced market specialization through focus on hospital pharmaceuticals
  • Differentiated product lineup via abundant formulation technology
  • Reliable product supply through advanced quality control
  • Trust building via collaborations with local governments and academia
  • High market responsiveness with multifaceted sales channels
  • Operational efficiency via infrastructure development and optimized pharmaceutical logistics
  • Global strategy focused on innovation
  • Accelerated R&D possible with diverse specialized talent

Threats

  • Rising new drug development costs and declining success rates
  • Intensifying competition with strong domestic and international rivals
  • Generics market entry upon patent expiration
  • Drug price reduction pressures from healthcare reforms
  • Risks from stricter regulations and approval delays
  • Currency fluctuation impacts on overseas sales and profits
  • Political risks in global markets
  • Uncertainties from emerging infectious diseases and pandemics
  • Industry structure changes from rapid technological innovation
  • Data security and privacy risks
  • Supply disruptions from supply chain breaks
  • Brand image impacts from pharmaceutical safety issues

Innovations

2024: AI utilization for efficient anticancer drug candidate screening

Overview
Developed technology using AI to rapidly identify effective drug candidates from vast data.
Impact
Contributes to shortening new drug development timelines and reducing R&D costs

2023: Expansion of global co-development for Enhertu

Overview
Strengthening collaboration with Korean biotech to expand Enhertu indications.
Impact
Enhances competitiveness in oncology

2023: Establishment of next-generation vaccine production technology

Overview
Introduced high-efficiency, low-cost vaccine manufacturing process domestically.
Impact
Achieves improved manufacturing capacity and stable supply

2022: Renewal of biopharmaceutical manufacturing platform

Overview
Introduced new cell culture and analysis techniques to improve quality and productivity.
Impact
Contributes to maintaining and expanding competitive edge

2021: Development of medication adherence support system via digital health collaboration

Overview
Launched patient medication management support service using mobile apps.
Impact
Improves treatment outcomes and customer satisfaction

2021: Acceleration of novel antibody pharmaceutical development

Overview
Expanded development pipeline using innovative antibody technology.
Impact
Expected future sales growth

2020: Launch of Japan's first tumor immunotherapy cell therapy research

Overview
Initiated research on groundbreaking cell therapy technology in cancer immunotherapy.
Impact
Strengthens foundation for next-generation cancer treatments

2020: Advanced antibody drug discovery platform

Overview
Improved antibody drug candidate identification speed via AI and automation.
Impact
Significant improvement in R&D efficiency

2020: Preparation of investigational drug manufacturing infrastructure

Overview
Strengthened quality assurance for investigational drugs to support domestic and international approvals.
Impact
Contributes to shortening time to market for new drugs

2020: Manufacturing process innovation for reduced environmental impact

Overview
Introduced manufacturing technology balancing energy savings and waste reduction.
Impact
Improves environmental responsiveness and cost efficiency

Sustainability

  • CO2 emissions reduction via green energy introduction
  • Waste recycling promotion in manufacturing processes
  • Health education support activities in local communities
  • Diversity promotion and inclusion enhancement
  • Establishment of sustainable procurement policies
  • In-house environmental conservation campaign events
  • Awareness activities for proper pharmaceutical use
  • International certification of environmental management systems
  • Promotion of employee health programs
  • Introduction of CSR evaluation standards for business partners
  • Strengthened water resource management and conservation measures
  • Support for local volunteer activities